Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Authors :: Daniel V.T. Catenacci
Jon M. Wigginton
Philip J. Gold
T. Wu
Hope E. Uronis
Keun Wook Lee
Haeseong Park
J. Yen
A. Wynter-Horton
Y.-J. Bang
Aleksandra Franovic
John Muth
Peter C. Enzinger
Jill Lacy
Justin I. Odegaard
Y-K. Kang
M.C.H. Ng
Sung-Ji Park
Jan Baughman
Jan K Davidson-Moncada
Source :: Annals of Oncology. 29:viii223
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Antitumor activity
business.industry
Margetuximab
Hematology
Pembrolizumab
03 medical and health sciences
Gastric adenocarcinoma
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
Biomarker (medicine)
Medicine
In patient
business

Full Text Access

Tools